Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results